References
- Schuknecht HF. Ablation therapy in the management of Ménière's disease. Acta Otolaryngol Suppl 1957; 132: 1–41
- Blakley BW. Update on intratympanic gentamicin for Ménière's disease. Laryngoscope 2000; 110: 236–40
- Colletti V, Carner M, Colletti L. Auditory results after vestibular nerve section and intratympanic gentamicin for Ménière's disease. Otol Neurotol 2007; 28: 145–51
- Kaplan DM, Nedzelski JM, Al-Abidi A, Chen JM, Shipp DB. Hearing loss following inratympanic instillation of gentamicin for the treatment of unilateral Meniere's disease. J Otolaryngol 2002; 31: 106–11
- Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. Laryngoscope 2003; 113: 815–20
- Martin E, Perez N. Hearing loss after intratympanic gentamicin therapy for unilateral Ménière's disease. Otol Neurotol 2003; 24: 800–6
- Perez N, Boleas M, Martin E. Distortion product otoacoustic emissions after intratympanic gentamicin therapy for unilateral Ménière's disease. Audiol Neurotol 2005; 10: 69–78
- Nakashima T, Teranishi M, Hibi T, Kobayashi M, Umemura M. Vestibular and cochlear toxicity of aminoglycosides – a review. Acta Otolaryngol (Stockh) 2000; 120: 904–11
- Isoherranen N, Lavy E, Soback S. Pharmacokinetics of gentamicin C1, C1a and C2 in beagles after a single intravenous dose. Antimicrob Agents Chemother 2000; 44: 1443–7
- Forrey AW, Meijsen-Ludwick BT, O'Neill MA, Maxwell BM, Blair AD, Cutler RE. Nephrotoxicity: a comparison in humans of gentamicin and gentamicin C1 administration. Toxicol Appl Pharmacol 1978; 44: 453–62
- Fox KE, Brummett RE, Brown R, Himes D. A comparative study of the ototoxicity of gentamicin and gentamicin C1. Arch Otolaryngol 1980; 106: 44–9
- Kobayashi M, Umemura M, Sone M, Nakashima T. Differing effects on inner ear of three gentamicin compounds: GM-C1, GM-C2 and GM-C1a. Acta Otolaryngol (Stockh) 2003; 123: 916–22
- White LO, Lovering A, Reeves DS. Variations in gentamicin C1, C1a, C2, and C2a content of some preparations of gentamicin sulphate used clinically as determined by high-performance liquid chromatography. Ther Drug Monit 1983; 5: 123–6
- Isoherranen N, Soback S. Determination of gentamicins C1, C1a, and C2 in plasma and urine by HPLC. Clin Chem 2000; 46: 837–42
- Steinman A, Isoherranen N, Ashoach O, Soback S. Pharmacokinetics of gentamicin C1, C1a and C2 in horses after single intravenous dose. Equine Vet J 2002; 34: 615–18
- Molitoris BA. Cell biology of aminoglycoside nephrotoxicity: newer aspects. Curr Opin Nephrol Hypertens 1997; 6: 384–8
- Light JP, Silverstein H, Jackson LE. Gentamicin perfusion vestibular response and hearing loss. Otol Neurotol 2003; 24: 294–8
- Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol 2004; 25: 544–52